JP2009529926A - ゲル化複合体 - Google Patents
ゲル化複合体 Download PDFInfo
- Publication number
- JP2009529926A JP2009529926A JP2008557416A JP2008557416A JP2009529926A JP 2009529926 A JP2009529926 A JP 2009529926A JP 2008557416 A JP2008557416 A JP 2008557416A JP 2008557416 A JP2008557416 A JP 2008557416A JP 2009529926 A JP2009529926 A JP 2009529926A
- Authority
- JP
- Japan
- Prior art keywords
- foam
- gel
- alginate
- ions
- polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000006260 foam Substances 0.000 claims abstract description 447
- 150000002500 ions Chemical class 0.000 claims abstract description 137
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 124
- 239000005017 polysaccharide Substances 0.000 claims abstract description 124
- 238000000034 method Methods 0.000 claims abstract description 72
- 239000002131 composite material Substances 0.000 claims abstract description 69
- 239000011148 porous material Substances 0.000 claims abstract description 68
- 239000007788 liquid Substances 0.000 claims abstract description 49
- 229920000642 polymer Polymers 0.000 claims abstract description 26
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 15
- 206010052428 Wound Diseases 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 230000017423 tissue regeneration Effects 0.000 claims abstract description 13
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 7
- 238000005187 foaming Methods 0.000 claims abstract description 7
- 150000004676 glycans Chemical class 0.000 claims abstract 31
- 235000010443 alginic acid Nutrition 0.000 claims description 183
- 229920000615 alginic acid Polymers 0.000 claims description 183
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 182
- 229940072056 alginate Drugs 0.000 claims description 176
- 239000000243 solution Substances 0.000 claims description 120
- 239000000499 gel Substances 0.000 claims description 110
- 229920001661 Chitosan Polymers 0.000 claims description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 35
- 239000007864 aqueous solution Substances 0.000 claims description 30
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 25
- 235000010418 carrageenan Nutrition 0.000 claims description 25
- 229920001525 carrageenan Polymers 0.000 claims description 25
- 229910001424 calcium ion Inorganic materials 0.000 claims description 24
- 239000011575 calcium Substances 0.000 claims description 23
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 22
- 229910052791 calcium Inorganic materials 0.000 claims description 21
- 239000000679 carrageenan Substances 0.000 claims description 21
- 229940113118 carrageenan Drugs 0.000 claims description 21
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 21
- 230000010261 cell growth Effects 0.000 claims description 19
- 238000001035 drying Methods 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 15
- 239000004604 Blowing Agent Substances 0.000 claims description 15
- 238000001879 gelation Methods 0.000 claims description 15
- 238000005406 washing Methods 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 229940014041 hyaluronate Drugs 0.000 claims description 14
- 239000004615 ingredient Substances 0.000 claims description 14
- 239000006185 dispersion Substances 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 11
- 239000001814 pectin Substances 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 229910052712 strontium Inorganic materials 0.000 claims description 11
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 11
- 229910001427 strontium ion Inorganic materials 0.000 claims description 11
- 229920001277 pectin Polymers 0.000 claims description 10
- 235000010987 pectin Nutrition 0.000 claims description 10
- 230000004663 cell proliferation Effects 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 238000011065 in-situ storage Methods 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 238000013268 sustained release Methods 0.000 claims description 9
- 239000012730 sustained-release form Substances 0.000 claims description 9
- 229920001222 biopolymer Polymers 0.000 claims description 7
- 229940045110 chitosan Drugs 0.000 claims description 7
- 239000002250 absorbent Substances 0.000 claims description 6
- 230000002745 absorbent Effects 0.000 claims description 6
- 239000002158 endotoxin Substances 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 239000003205 fragrance Substances 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 239000003002 pH adjusting agent Substances 0.000 claims description 5
- 229960000292 pectin Drugs 0.000 claims description 5
- 239000004014 plasticizer Substances 0.000 claims description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 229940005740 hexametaphosphate Drugs 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- 208000031737 Tissue Adhesions Diseases 0.000 claims description 2
- 230000000181 anti-adherent effect Effects 0.000 claims description 2
- 229910052788 barium Inorganic materials 0.000 claims description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 2
- 230000004888 barrier function Effects 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000003431 cross linking reagent Substances 0.000 claims description 2
- 238000010907 mechanical stirring Methods 0.000 claims description 2
- 238000000465 moulding Methods 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 2
- 229910001422 barium ion Inorganic materials 0.000 claims 2
- 235000013355 food flavoring agent Nutrition 0.000 claims 2
- 235000013376 functional food Nutrition 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 230000003204 osmotic effect Effects 0.000 claims 2
- 239000000853 adhesive Substances 0.000 claims 1
- 230000021164 cell adhesion Effects 0.000 claims 1
- 238000007598 dipping method Methods 0.000 claims 1
- 230000003100 immobilizing effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 159000000008 strontium salts Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 98
- 150000004804 polysaccharides Chemical class 0.000 description 92
- 238000002156 mixing Methods 0.000 description 28
- -1 cation salt Chemical class 0.000 description 24
- 150000001768 cations Chemical class 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 23
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 22
- 229960005069 calcium Drugs 0.000 description 21
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 20
- 239000000463 material Substances 0.000 description 20
- 235000010413 sodium alginate Nutrition 0.000 description 20
- 239000000661 sodium alginate Substances 0.000 description 20
- 229940005550 sodium alginate Drugs 0.000 description 20
- 229920006395 saturated elastomer Polymers 0.000 description 17
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 15
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 15
- 229920002674 hyaluronan Polymers 0.000 description 15
- 229920002307 Dextran Polymers 0.000 description 14
- 229960003160 hyaluronic acid Drugs 0.000 description 14
- 235000010355 mannitol Nutrition 0.000 description 14
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 13
- 229930195725 Mannitol Natural products 0.000 description 13
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 13
- 239000000594 mannitol Substances 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 239000004094 surface-active agent Substances 0.000 description 13
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 12
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 235000012209 glucono delta-lactone Nutrition 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 12
- 239000000600 sorbitol Substances 0.000 description 12
- 229960002920 sorbitol Drugs 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 229910000019 calcium carbonate Inorganic materials 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 11
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 241001466453 Laminaria Species 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000004088 foaming agent Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000012981 Hank's balanced salt solution Substances 0.000 description 7
- IAJILQKETJEXLJ-SQOUGZDYSA-N L-guluronic acid Chemical compound O=C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-SQOUGZDYSA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 229920000136 polysorbate Polymers 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 241001474374 Blennius Species 0.000 description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- 229910052802 copper Inorganic materials 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000000017 hydrogel Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229960002378 oftasceine Drugs 0.000 description 6
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 6
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 5
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 5
- 229960001126 alginic acid Drugs 0.000 description 5
- 239000000783 alginic acid Substances 0.000 description 5
- 150000004781 alginic acids Chemical class 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229960002713 calcium chloride Drugs 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 239000007799 cork Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 229920002274 Nalgene Polymers 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 239000004809 Teflon Substances 0.000 description 4
- 229920006362 Teflon® Polymers 0.000 description 4
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 4
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000004581 coalescence Methods 0.000 description 4
- 238000003381 deacetylation reaction Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 239000003068 molecular probe Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 230000001012 protector Effects 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000001226 triphosphate Substances 0.000 description 4
- 108010072644 valyl-alanyl-prolyl-glycine Proteins 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- PPINMSZPTPRQQB-NHCYSSNCSA-N 2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PPINMSZPTPRQQB-NHCYSSNCSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241001512709 Lessonia <stramenopiles> Species 0.000 description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- HXNZTJULPKRNPR-UHFFFAOYSA-N borinine Chemical compound B1=CC=CC=C1 HXNZTJULPKRNPR-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000006196 deacetylation Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 101100496858 Mus musculus Colec12 gene Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 229920006318 anionic polymer Polymers 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000007444 cell Immobilization Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- AEMOLEFTQBMNLQ-YBSDWZGDSA-N d-mannuronic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-YBSDWZGDSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000006261 foam material Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000000182 glucono-delta-lactone Substances 0.000 description 2
- 229960003681 gluconolactone Drugs 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 125000005613 guluronic acid group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- PWYYWQHXAPXYMF-UHFFFAOYSA-N strontium(2+) Chemical compound [Sr+2] PWYYWQHXAPXYMF-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 230000009772 tissue formation Effects 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 238000009827 uniform distribution Methods 0.000 description 2
- 238000002689 xenotransplantation Methods 0.000 description 2
- NTEDOEBWPRVVSG-FQUUOJAGSA-N (2s)-1-[(2r)-2-[[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CO)C(=O)N1CCC[C@H]1C(O)=O NTEDOEBWPRVVSG-FQUUOJAGSA-N 0.000 description 1
- QAQSNXHKHKONNS-UHFFFAOYSA-N 1-ethyl-2-hydroxy-4-methyl-6-oxopyridine-3-carboxamide Chemical compound CCN1C(O)=C(C(N)=O)C(C)=CC1=O QAQSNXHKHKONNS-UHFFFAOYSA-N 0.000 description 1
- JKTAIYGNOFSMCE-UHFFFAOYSA-N 2,3-di(nonyl)phenol Chemical compound CCCCCCCCCC1=CC=CC(O)=C1CCCCCCCCC JKTAIYGNOFSMCE-UHFFFAOYSA-N 0.000 description 1
- XSXWOBXNYNULJG-UHFFFAOYSA-N 2-(2,4,4-trimethylpentan-2-yl)phenol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1O XSXWOBXNYNULJG-UHFFFAOYSA-N 0.000 description 1
- SZBYVOSSTHEBFR-UHFFFAOYSA-N 2-(2-methyloctan-2-yl)phenol Chemical compound CCCCCCC(C)(C)C1=CC=CC=C1O SZBYVOSSTHEBFR-UHFFFAOYSA-N 0.000 description 1
- BTMZHHCFEOXAAN-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;2-dodecylbenzenesulfonic acid Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCC1=CC=CC=C1S(O)(=O)=O BTMZHHCFEOXAAN-UHFFFAOYSA-N 0.000 description 1
- LIFHMKCDDVTICL-UHFFFAOYSA-N 6-(chloromethyl)phenanthridine Chemical compound C1=CC=C2C(CCl)=NC3=CC=CC=C3C2=C1 LIFHMKCDDVTICL-UHFFFAOYSA-N 0.000 description 1
- 241000722818 Aralia Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000034628 Celiac artery compression syndrome Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000195480 Fucus Species 0.000 description 1
- 241000227647 Fucus vesiculosus Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- FZHXIRIBWMQPQF-UHFFFAOYSA-N Glc-NH2 Natural products O=CC(N)C(O)C(O)C(O)CO FZHXIRIBWMQPQF-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241001441571 Hiodontidae Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241001598113 Laminaria digitata Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 241001491708 Macrocystis Species 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KFEUJDWYNGMDBV-LODBTCKLSA-N N-acetyllactosamine Chemical group O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-LODBTCKLSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000015177 Saccharina japonica Species 0.000 description 1
- 241000983746 Saccharina latissima Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- KERUZGTVFOVXPQ-ROYBBBCZSA-N [(1R)-1-[(2S,3S,4R)-3,4-dihydroxyoxolan-2-yl]-2-oxoethyl] hydrogen sulfate [(2R,3S,4R,5R)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl] hydrogen sulfate Chemical compound O[C@@H]1CO[C@H]([C@@H](OS(O)(=O)=O)C=O)[C@H]1O.OC[C@@H](O)[C@H](OS(O)(=O)=O)[C@H](O)[C@@H](O)C=O KERUZGTVFOVXPQ-ROYBBBCZSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- REDXJYDRNCIFBQ-UHFFFAOYSA-N aluminium(3+) Chemical compound [Al+3] REDXJYDRNCIFBQ-UHFFFAOYSA-N 0.000 description 1
- 235000019824 amidated pectin Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 229940045511 barium chloride Drugs 0.000 description 1
- XDFCIPNJCBUZJN-UHFFFAOYSA-N barium(2+) Chemical compound [Ba+2] XDFCIPNJCBUZJN-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003848 cartilage regeneration Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000012598 cell culture matrix Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000000501 collagen implant Substances 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- ODDZENUCCGSDGC-UHFFFAOYSA-N copper;n'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-diamine;gold(1+);tetracyanide Chemical compound [Cu+2].[Au+].[Au+].N#[C-].N#[C-].N#[C-].N#[C-].NCCNCCNCCNCCN ODDZENUCCGSDGC-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- AGDZIJFMSISITG-UHFFFAOYSA-L disodium 2-oxopropanoate Chemical compound [Na+].[Na+].CC(=O)C([O-])=O.CC(=O)C([O-])=O AGDZIJFMSISITG-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 108010053299 glycyl-arginyl-glycyl-aspartyl-seryl-proline Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- BDAGIHXWWSANSR-NJFSPNSNSA-N hydroxyformaldehyde Chemical compound O[14CH]=O BDAGIHXWWSANSR-NJFSPNSNSA-N 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 229920005684 linear copolymer Polymers 0.000 description 1
- GUQXQVVVMILANR-UHFFFAOYSA-N lithium;magnesium Chemical compound [Li+].[Mg+2] GUQXQVVVMILANR-UHFFFAOYSA-N 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000000569 multi-angle light scattering Methods 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 238000009828 non-uniform distribution Methods 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- KXGMKEGVOWZAAY-UHFFFAOYSA-M sodium 3-carboxy-3,5-dihydroxy-5-oxopentanoate 2-hydroxypropane-1,2,3-tricarboxylic acid dihydrate Chemical compound O.O.C(CC(O)(C(=O)O)CC(=O)O)(=O)[O-].[Na+].C(CC(O)(C(=O)O)CC(=O)O)(=O)O KXGMKEGVOWZAAY-UHFFFAOYSA-M 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940080236 sodium cetyl sulfate Drugs 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 229950005425 sodium myristyl sulfate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- NWZBFJYXRGSRGD-UHFFFAOYSA-M sodium;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O NWZBFJYXRGSRGD-UHFFFAOYSA-M 0.000 description 1
- UPUIQOIQVMNQAP-UHFFFAOYSA-M sodium;tetradecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCOS([O-])(=O)=O UPUIQOIQVMNQAP-UHFFFAOYSA-M 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229910000018 strontium carbonate Inorganic materials 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- 229940013553 strontium chloride Drugs 0.000 description 1
- 229940047908 strontium chloride hexahydrate Drugs 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- AMGRXJSJSONEEG-UHFFFAOYSA-L strontium dichloride hexahydrate Chemical compound O.O.O.O.O.O.Cl[Sr]Cl AMGRXJSJSONEEG-UHFFFAOYSA-L 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003784 tall oil Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229940105956 tea-dodecylbenzenesulfonate Drugs 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Materials Engineering (AREA)
- Composite Materials (AREA)
- Botany (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- Surgery (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
- Cosmetics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Glass Compositions (AREA)
- Colloid Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77786906P | 2006-03-01 | 2006-03-01 | |
| US87284406P | 2006-12-05 | 2006-12-05 | |
| US87417406P | 2006-12-11 | 2006-12-11 | |
| PCT/US2007/005436 WO2007103209A2 (en) | 2006-03-01 | 2007-03-01 | Gelled composite |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009529926A true JP2009529926A (ja) | 2009-08-27 |
| JP2009529926A5 JP2009529926A5 (https=) | 2010-04-15 |
Family
ID=38328938
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008557416A Ceased JP2009529926A (ja) | 2006-03-01 | 2007-03-01 | ゲル化複合体 |
| JP2008557415A Pending JP2009528437A (ja) | 2006-03-01 | 2007-03-01 | 生分解性発泡体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008557415A Pending JP2009528437A (ja) | 2006-03-01 | 2007-03-01 | 生分解性発泡体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20070254016A1 (https=) |
| EP (2) | EP1988937A2 (https=) |
| JP (2) | JP2009529926A (https=) |
| AT (1) | ATE517645T1 (https=) |
| AU (2) | AU2007224137A1 (https=) |
| BR (2) | BRPI0708429A2 (https=) |
| CA (2) | CA2643083A1 (https=) |
| IL (2) | IL193640A (https=) |
| NO (2) | NO20083696L (https=) |
| WO (2) | WO2007103208A2 (https=) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013544549A (ja) * | 2010-10-08 | 2013-12-19 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム | 生物医学的応用のためのアルギン酸塩及びヒアルロン酸を用いる抗癒着性バリア膜 |
| WO2014192807A1 (ja) * | 2013-05-29 | 2014-12-04 | 株式会社大塚製薬工場 | 癒着防止材 |
| JP2016502874A (ja) * | 2012-12-11 | 2016-02-01 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 癒着防止のためのハイドロゲル膜 |
| WO2022070845A1 (ja) * | 2020-09-29 | 2022-04-07 | 日東電工株式会社 | 発泡体及びその製造方法 |
| US11565027B2 (en) | 2012-12-11 | 2023-01-31 | Board Of Regents, The University Of Texas System | Hydrogel membrane for adhesion prevention |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8668737B2 (en) | 1997-10-10 | 2014-03-11 | Senorx, Inc. | Tissue marking implant |
| US8361082B2 (en) | 1999-02-02 | 2013-01-29 | Senorx, Inc. | Marker delivery device with releasable plug |
| US9820824B2 (en) | 1999-02-02 | 2017-11-21 | Senorx, Inc. | Deployment of polysaccharide markers for treating a site within a patent |
| US7983734B2 (en) | 2003-05-23 | 2011-07-19 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
| US7877133B2 (en) | 2003-05-23 | 2011-01-25 | Senorx, Inc. | Marker or filler forming fluid |
| GB0508531D0 (en) | 2005-04-27 | 2005-06-01 | Smith & Nephew | Sai with ultrasound |
| US9579077B2 (en) | 2006-12-12 | 2017-02-28 | C.R. Bard, Inc. | Multiple imaging mode tissue marker |
| EP2155810A4 (en) * | 2007-06-13 | 2013-07-03 | Fmc Corp | ALGINATE-COATED, POLYSAC-CHARIDE-CONTAINING FOAM COMPOSITE, MANUFACTURING METHOD AND USES THEREOF |
| DE102007037051A1 (de) * | 2007-07-24 | 2009-01-29 | Aesculap Ag | Flächiges Implantat |
| US8221783B2 (en) * | 2007-09-10 | 2012-07-17 | Boston Scientific Scimed, Inc. | Medical devices with triggerable bioadhesive material |
| WO2009038783A1 (en) * | 2007-09-19 | 2009-03-26 | Surmodics, Inc. | Biocompatible foams, systems, and methods |
| DE102007051059B4 (de) * | 2007-10-18 | 2014-04-03 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Bioverbundmaterial für die kontrollierte Freisetzung von Wirkstoffen |
| US8673354B2 (en) | 2007-11-05 | 2014-03-18 | Technion Research And Development Foundation Ltd. | Adhesives and methods of applying the same |
| GB0722820D0 (en) | 2007-11-21 | 2008-01-02 | Smith & Nephew | Vacuum assisted wound dressing |
| ES2555204T3 (es) | 2007-11-21 | 2015-12-29 | T.J. Smith & Nephew Limited | Dispositivo de succión y venda |
| ES2776709T3 (es) | 2007-11-21 | 2020-07-31 | Smith & Nephew | Apósito para heridas |
| US11253399B2 (en) | 2007-12-06 | 2022-02-22 | Smith & Nephew Plc | Wound filling apparatuses and methods |
| GB0723875D0 (en) | 2007-12-06 | 2008-01-16 | Smith & Nephew | Wound management |
| US20130096518A1 (en) | 2007-12-06 | 2013-04-18 | Smith & Nephew Plc | Wound filling apparatuses and methods |
| GB0803564D0 (en) | 2008-02-27 | 2008-04-02 | Smith & Nephew | Fluid collection |
| US9327061B2 (en) * | 2008-09-23 | 2016-05-03 | Senorx, Inc. | Porous bioabsorbable implant |
| GB0902816D0 (en) | 2009-02-19 | 2009-04-08 | Smith & Nephew | Fluid communication path |
| WO2010117266A1 (en) | 2009-04-06 | 2010-10-14 | Broockeville Corporation N.V. | In situ gelling alginate systems |
| EP2437797B1 (en) | 2009-06-01 | 2013-08-14 | Technion Research & Development Foundation Ltd. | Multi components adhesives, manufacturing thereof, and applications thereof |
| IN2012DN01100A (https=) * | 2009-08-07 | 2015-04-10 | Fmc Corp | |
| US10207022B2 (en) * | 2009-09-01 | 2019-02-19 | Medoderm Gmbh | Chitosan tissue dressing |
| US9061095B2 (en) | 2010-04-27 | 2015-06-23 | Smith & Nephew Plc | Wound dressing and method of use |
| JP5937070B2 (ja) * | 2010-06-22 | 2016-06-22 | ウニヴェルシテ ド ルアンＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｒｏｕｅｎ | ３ｄ細胞培養に用いる改良された架橋ヒアルロナンヒドロゲル |
| GB201011173D0 (en) | 2010-07-02 | 2010-08-18 | Smith & Nephew | Provision of wound filler |
| JP6078472B2 (ja) | 2010-11-25 | 2017-02-08 | スミス アンド ネフュー ピーエルシーＳｍｉｔｈ ＆ Ｎｅｐｈｅｗ Ｐｕｂｌｉｃ Ｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ | 組成物ｉ−ｉｉおよび生成物ならびにそれらの使用 |
| GB201020005D0 (en) | 2010-11-25 | 2011-01-12 | Smith & Nephew | Composition 1-1 |
| EP2688397B1 (en) | 2011-03-21 | 2016-07-20 | University of Reading | Transport of cells in alginate hydrogels |
| WO2012149242A1 (en) * | 2011-04-29 | 2012-11-01 | Kci Licensing, Inc. | Aptamer -modified polymeric materials for the binding of therapeutic factors in a wound environment |
| RU2471824C1 (ru) * | 2011-07-26 | 2013-01-10 | Учреждение Российской академии наук Институт высокомолекулярных соединений РАН | Биосовместимый биодеградируемый пористый композиционный материал и способ его получения |
| US20150159066A1 (en) | 2011-11-25 | 2015-06-11 | Smith & Nephew Plc | Composition, apparatus, kit and method and uses thereof |
| US20130288932A1 (en) * | 2012-04-27 | 2013-10-31 | Halliburton Energy Services, Inc. | Methods of cryodesiccating a broth comprising a biopolymer of an exopolysaccharide |
| WO2014039414A1 (en) * | 2012-09-07 | 2014-03-13 | 3M Innovative Properties Company | Silcone compositions and related methods |
| CA2893064C (en) * | 2012-12-07 | 2021-05-04 | Baxter International Inc. | Hemostatic foam |
| US20140242676A1 (en) * | 2013-02-01 | 2014-08-28 | Los Alamos National Security, Llc | Artificial leaf-like microphotobioreactor and methods for making the same |
| EP2968647B1 (en) | 2013-03-15 | 2022-06-29 | Smith & Nephew plc | Wound dressing sealant and use thereof |
| US20160120706A1 (en) | 2013-03-15 | 2016-05-05 | Smith & Nephew Plc | Wound dressing sealant and use thereof |
| FR3039555B1 (fr) | 2015-07-30 | 2017-08-18 | Univ Toulouse Iii - Paul Sabatier | Procede de preparation de matrices poreuses polymeres biocompatibles et biodegradables trimensionnelles et applications |
| JP6719182B2 (ja) * | 2015-08-05 | 2020-07-08 | 株式会社武蔵野化学研究所 | エンドトキシンの測定用試料の前処理方法 |
| US20170157283A1 (en) | 2015-12-08 | 2017-06-08 | Medtronic Xomed, Inc. | Dissolvable nasal sinus sponge |
| CA3015172A1 (en) * | 2016-02-18 | 2017-08-24 | Privo Technologies, Inc. | Two-stage microparticle-based therapeutic delivery system and method |
| US11464597B2 (en) | 2016-07-13 | 2022-10-11 | The University Of Tokyo | Adhesion-preventing composition |
| EP3412710B1 (en) * | 2016-12-23 | 2021-11-10 | LG Chem, Ltd. | Method for producing porous superabsorbent polymer |
| WO2018151849A1 (en) * | 2017-02-17 | 2018-08-23 | Privo Technologies, Inc. | Particle-based multi-layer therapeutic delivery device and method |
| US10478403B1 (en) | 2017-05-03 | 2019-11-19 | Privo Technologies, Inc. | Intraoperative topically-applied non-implantable rapid release patch |
| FR3068039B1 (fr) | 2017-06-22 | 2020-07-10 | Jellynov | Composition auto-moussante en milieu acide et procede de preparation |
| US10980913B2 (en) | 2018-03-05 | 2021-04-20 | Ethicon Llc | Sealant foam compositions for lung applications |
| EP3873991A4 (en) | 2018-11-02 | 2022-07-27 | Covalon Technologies Inc. | FOAM COMPOSITIONS, FOAM MATRICES AND PROCESSES |
| FR3089224B1 (fr) | 2018-12-04 | 2020-12-11 | Jellynov | Composition auto-moussante en milieu acide et procédé de préparation |
| ES3044684T3 (en) * | 2019-02-07 | 2025-11-27 | Biorez Inc | Composite scaffold for the repair, reconstruction, and regeneration of soft tissues |
| EP3924061A1 (en) | 2019-02-15 | 2021-12-22 | Johnson & Johnson Consumer Inc. | Moldable gel cleanser |
| NL2022788B1 (en) * | 2019-03-22 | 2020-09-28 | No Ceuticals B V | Chitosan nitrate for use as a nitric oxide donor (NO donor) |
| US20220289999A1 (en) * | 2019-07-11 | 2022-09-15 | StenCo, LLC | Biodegradable material |
| CN110960722A (zh) * | 2019-12-14 | 2020-04-07 | 广东泰宝医疗科技股份有限公司 | 一种抗菌藻酸盐创口贴及其制备方法 |
| CN111888524A (zh) * | 2020-08-04 | 2020-11-06 | 宁波迪创医疗科技有限公司 | 一种组织填充材料及其制备方法、组织工程支架和应用 |
| KR20240041285A (ko) | 2021-06-01 | 2024-03-29 | 프리보 테크놀로지스, 인코포레이티드 | 향상된 2단계 미세입자 기반 국소 치료제 전달 시스템 |
| WO2023060076A1 (en) * | 2021-10-04 | 2023-04-13 | Cruz Foam, Inc. | Biodegradable foam with alginate |
| WO2023064542A1 (en) * | 2021-10-14 | 2023-04-20 | Kimberly-Clark Worldwide, Inc. | Biodegradable and renewable superabsorbent material |
| CN114403240B (zh) * | 2022-01-07 | 2023-07-21 | 华南农业大学 | 一种新型米糠蛋白基起酥油替代物及其在烘焙食品中的应用 |
| EP4417243A1 (de) * | 2023-02-15 | 2024-08-21 | Heraeus Medical GmbH | Implantat zur verzögerten wirkstofffreisetzung |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001514551A (ja) * | 1997-03-07 | 2001-09-11 | アボネティクス リミティッド | 組織移植体 |
| US20040071776A1 (en) * | 2000-11-22 | 2004-04-15 | Vincent Boudy | Porous plymeric biomaterials, preparation method and uses |
| JP2007068879A (ja) * | 2005-09-09 | 2007-03-22 | National Cardiovascular Center | 生体埋込部材及び人工組織 |
| JP2007143833A (ja) * | 2005-11-28 | 2007-06-14 | National Cardiovascular Center | 生体埋込部材及び人工組織 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2128551A (en) | 1934-01-11 | 1938-08-30 | Algin Corp Of America | Method of treating seaweed |
| US2036934A (en) | 1934-04-21 | 1936-04-07 | Kelco Co | Process for making alginic acid and product |
| US2246125A (en) * | 1941-04-01 | 1941-06-17 | Gen Electric | Electric discharge device |
| US2426125A (en) | 1944-04-03 | 1947-08-19 | Kelco Co | Manufacture of glycol alginates |
| US3772266A (en) * | 1972-10-19 | 1973-11-13 | Kelco Co | Process for the preparation of propylene glycol alginate from partially neutralized alginic acid |
| CA1019326A (en) * | 1974-07-16 | 1977-10-18 | Uniroyal Ltd. | Process for the production of alkylene glycol alginates |
| DE2437090A1 (de) * | 1974-08-01 | 1976-02-19 | Hoechst Ag | Reinigungsmittel |
| GB1570485A (en) | 1975-11-18 | 1980-07-02 | Robinson & Sons Ltd | Absorbent material for aqueous fluids |
| US4292972A (en) | 1980-07-09 | 1981-10-06 | E. R. Squibb & Sons, Inc. | Lyophilized hydrocolloio foam |
| US5735902A (en) | 1987-07-20 | 1998-04-07 | Regen Biologics, Inc. | Hand implant device |
| DE3832643A1 (de) * | 1988-09-26 | 1990-03-29 | Patent Treuhand Ges Fuer Elektrische Gluehlampen Mbh | Verfahren zur herstellung einer reflexionsbeschichtung bei hochdruckentladungslampen |
| US4948575A (en) | 1989-01-24 | 1990-08-14 | Minnesota Mining And Manufacturing Company | Alginate hydrogel foam wound dressing |
| US5260345A (en) * | 1991-08-12 | 1993-11-09 | The Procter & Gamble Company | Absorbent foam materials for aqueous body fluids and absorbent articles containing such materials |
| CA2080035A1 (en) | 1991-10-15 | 1993-04-16 | George Colegrove | Gelled foams |
| US5851461A (en) * | 1992-06-19 | 1998-12-22 | Albany International Research Co. | Method of producing polysaccharide foams |
| US5840777A (en) * | 1992-06-19 | 1998-11-24 | Albany International Corp. | Method of producing polysaccharide foams |
| CA2116037C (en) * | 1992-06-19 | 2000-01-04 | Dana B. Eagles | Method of producing polysaccharide foams |
| IL104441A (en) | 1993-01-19 | 2001-01-28 | Yossi Res Dev Company Of The H | Sponges from hydrocolloids and method for their production |
| US20030224022A1 (en) | 1993-01-19 | 2003-12-04 | Amos Nussinovitch | Hydrocolloid cellular solid matrices |
| US5709854A (en) * | 1993-04-30 | 1998-01-20 | Massachusetts Institute Of Technology | Tissue formation by injecting a cell-polymeric solution that gels in vivo |
| TW369414B (en) | 1994-09-30 | 1999-09-11 | Yamanouchi Pharma Co Ltd | Bone formation transplant |
| US6294202B1 (en) * | 1994-10-06 | 2001-09-25 | Genzyme Corporation | Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers |
| US5891558A (en) * | 1994-11-22 | 1999-04-06 | Tissue Engineering, Inc. | Biopolymer foams for use in tissue repair and reconstruction |
| US5709934A (en) | 1994-11-22 | 1998-01-20 | Tissue Engineering, Inc. | Bipolymer foams having extracellular matrix particulates |
| NO953115L (no) | 1995-06-07 | 1996-12-09 | Albany Int Research | Fremgangsmåte for fremstilling av polysakkaridskum |
| JP2822174B2 (ja) * | 1996-03-01 | 1998-11-11 | オーミケンシ株式会社 | キチンキトサン繊維及び構造体の製造法 |
| GB9608222D0 (en) | 1996-04-20 | 1996-06-26 | Innovative Tech Ltd | Dehydrated hydrogels |
| IL118376A0 (en) * | 1996-05-22 | 1996-09-12 | Univ Ben Gurion | Polysaccharide sponges for cell culture and transplantation |
| US6054142A (en) | 1996-08-01 | 2000-04-25 | Cyto Therapeutics, Inc. | Biocompatible devices with foam scaffolds |
| ES2317657T3 (es) * | 1996-09-19 | 2009-04-16 | The Regents Of The University Of Michigan | Polimeros que contienen polisacaridos tales como alginatos o alginatos modificados. |
| GB2318577B (en) | 1996-10-28 | 2000-02-02 | Johnson & Johnson Medical | Solvent dried polysaccharide sponges |
| ATE249491T1 (de) | 1997-03-31 | 2003-09-15 | Univ Michigan | Offenporige bioabbaubare matrize |
| JP2001520274A (ja) * | 1997-10-17 | 2001-10-30 | アドバンスト・メディカル・ソリューションズ・リミテッド | 発泡材料 |
| IL124957A0 (en) * | 1998-06-16 | 1999-01-26 | Univ Ben Gurion | Active ingredient delivery systems and devices based on porous matrices |
| KR100298846B1 (ko) | 1998-09-24 | 2003-10-22 | 한국원자력연구소 | 중화키토산스폰지또는중화키토산/콜라겐혼합스폰지를이용한인공진피 |
| US7128929B1 (en) * | 1999-04-29 | 2006-10-31 | Scherr George H | Alginate foam compositions |
| WO2001006973A1 (en) * | 1999-07-28 | 2001-02-01 | United States Surgical Corporation | Hyaluronic acid anti-adhesion barrier |
| JP4044291B2 (ja) * | 2000-01-24 | 2008-02-06 | クラレメディカル株式会社 | 水膨潤性高分子ゲルおよびその製造法 |
| AU2001234623A1 (en) | 2000-01-28 | 2001-08-07 | Orthogene, Inc. | Gel-infused sponges for tissue repair and augmentation |
| US20030095993A1 (en) * | 2000-01-28 | 2003-05-22 | Hanne Bentz | Gel-infused sponges for tissue repair and augmentation |
| IT1320163B1 (it) | 2000-02-15 | 2003-11-18 | Novamont Spa | Foglia e prodotti formati a base di amido espanso. |
| AU2000231640A1 (en) | 2000-03-03 | 2001-09-12 | Rolf Siegel | Agent for the treatment of wounds |
| US6565960B2 (en) | 2000-06-01 | 2003-05-20 | Shriners Hospital Of Children | Polymer composite compositions |
| JP4493826B2 (ja) * | 2000-09-29 | 2010-06-30 | 株式会社クラレ | 多糖類スポンジの製造法及び多糖類スポンジ |
| US7041868B2 (en) * | 2000-12-29 | 2006-05-09 | Kimberly-Clark Worldwide, Inc. | Bioabsorbable wound dressing |
| US20050147656A1 (en) * | 2001-06-14 | 2005-07-07 | Hemcon, Inc. | Tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan |
| BR0210406A (pt) * | 2001-06-14 | 2006-04-04 | Providence Health Sys Oregon | curativo de ferimento, e, métodos de controle de sangramento severo, e de produção de um curativo de ferimento capaz de controlar o sangramento severo |
| US20060004314A1 (en) * | 2001-06-14 | 2006-01-05 | Hemcon, Inc. | Antimicrobial barriers, systems, and methods formed from hydrophilic polymer structures such as chistosan |
| US7371403B2 (en) | 2002-06-14 | 2008-05-13 | Providence Health System-Oregon | Wound dressing and method for controlling severe, life-threatening bleeding |
| US6696077B2 (en) | 2001-07-26 | 2004-02-24 | George H. Scherr | Silver alginate foam compositions |
| US20030186826A1 (en) | 2001-11-01 | 2003-10-02 | The Procter & Gamble Company | Method of using personal care compositions containing a high density, water disintegratable, polymeric foam |
| US20030180242A1 (en) | 2001-11-01 | 2003-09-25 | The Procter & Gamble Company | Personal care compositions containing a water-disintegratable polymeric foam |
| WO2003089506A1 (en) | 2002-04-22 | 2003-10-30 | Purdue Research Foundation | Hydrogels having enhanced elasticity and mechanical strength properties |
| US20050137512A1 (en) * | 2003-12-23 | 2005-06-23 | Campbell Todd D. | Wound dressing and method for controlling severe, life-threatening bleeding |
| US7993922B2 (en) * | 2002-10-18 | 2011-08-09 | Reliance Life Sciences Pvt. Ltd. | Three-dimensional tissue equivalent using macromass culture |
| US20040082063A1 (en) * | 2002-10-18 | 2004-04-29 | Reliance Life Sciences Pvt. Ltd. | Tissue-like organization of cells and macroscopic tissue-like constructs, generated by macromass culture of cells, and the method of macromass culture |
| KR100984184B1 (ko) | 2003-03-18 | 2010-09-28 | 에스케이케미칼주식회사 | 알긴산 스폰지 및 그의 제조방법 |
| US7674837B2 (en) | 2003-09-08 | 2010-03-09 | Fmc Biopolymer As | Gelled biopolymer based foam |
| CA2548305C (en) | 2003-12-23 | 2014-07-15 | Fmc Biopolymer As | Use of alginate matrices to control cell growth |
| GB0329773D0 (en) * | 2003-12-23 | 2004-01-28 | Perry Forbes G D | Torque equalisation in toric transmissions |
| US20050148963A1 (en) * | 2004-01-05 | 2005-07-07 | Brennan H. G. | Bioabsorbable surgical sponge |
| CN1297600C (zh) | 2004-07-30 | 2007-01-31 | 胡靖� | 环保防伪型全生物降解塑料发泡及流延成型方法 |
| EP1799232B1 (en) * | 2004-10-12 | 2015-10-07 | FMC Biopolymer AS | Self-gelling alginate systems and uses thereof |
| US7700355B2 (en) * | 2005-01-07 | 2010-04-20 | Industrial Technology Research Institute | Methods of producing a porous matrix for culturing and recovering cells |
| WO2007070660A2 (en) | 2005-12-13 | 2007-06-21 | President And Fellows Of Harvard College | Scaffolds for cell transplantation |
| US20070249044A1 (en) * | 2006-01-30 | 2007-10-25 | University Of Illinois At Chicago | Microstructures in three dimensional gel suspensions for growth of cells |
| CN100415304C (zh) | 2006-03-13 | 2008-09-03 | 西北大学 | 一种可生物降解止血海绵材料及其制备方法 |
| US20070240080A1 (en) * | 2006-04-11 | 2007-10-11 | Invensys Systems, Inc. | Strategy editor for process control supporting drag and drop connections to declarations |
-
2007
- 2007-03-01 CA CA 2643083 patent/CA2643083A1/en not_active Abandoned
- 2007-03-01 US US11/712,611 patent/US20070254016A1/en not_active Abandoned
- 2007-03-01 EP EP20070752153 patent/EP1988937A2/en not_active Withdrawn
- 2007-03-01 CA CA2643084A patent/CA2643084C/en not_active Expired - Fee Related
- 2007-03-01 BR BRPI0708429-3A patent/BRPI0708429A2/pt not_active IP Right Cessation
- 2007-03-01 AT AT07752154T patent/ATE517645T1/de not_active IP Right Cessation
- 2007-03-01 BR BRPI0708422-6A patent/BRPI0708422A2/pt not_active IP Right Cessation
- 2007-03-01 JP JP2008557416A patent/JP2009529926A/ja not_active Ceased
- 2007-03-01 WO PCT/US2007/005435 patent/WO2007103208A2/en not_active Ceased
- 2007-03-01 US US11/712,612 patent/US9028872B2/en not_active Expired - Fee Related
- 2007-03-01 AU AU2007224137A patent/AU2007224137A1/en not_active Abandoned
- 2007-03-01 WO PCT/US2007/005436 patent/WO2007103209A2/en not_active Ceased
- 2007-03-01 JP JP2008557415A patent/JP2009528437A/ja active Pending
- 2007-03-01 EP EP20070752154 patent/EP1988942B1/en not_active Not-in-force
- 2007-03-01 AU AU2007224138A patent/AU2007224138B2/en not_active Ceased
-
2008
- 2008-08-21 IL IL193640A patent/IL193640A/en not_active IP Right Cessation
- 2008-08-21 IL IL193621A patent/IL193621A/en not_active IP Right Cessation
- 2008-08-27 NO NO20083696A patent/NO20083696L/no not_active Application Discontinuation
- 2008-08-29 NO NO20083729A patent/NO20083729L/no not_active Application Discontinuation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001514551A (ja) * | 1997-03-07 | 2001-09-11 | アボネティクス リミティッド | 組織移植体 |
| US20040071776A1 (en) * | 2000-11-22 | 2004-04-15 | Vincent Boudy | Porous plymeric biomaterials, preparation method and uses |
| JP2007068879A (ja) * | 2005-09-09 | 2007-03-22 | National Cardiovascular Center | 生体埋込部材及び人工組織 |
| JP2007143833A (ja) * | 2005-11-28 | 2007-06-14 | National Cardiovascular Center | 生体埋込部材及び人工組織 |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10314950B2 (en) | 2010-10-08 | 2019-06-11 | Board Of Regents, The University Of Texas System | Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications |
| US11058802B2 (en) | 2010-10-08 | 2021-07-13 | Board Of Regents, The University Of Texas System | Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications |
| US11857701B2 (en) | 2010-10-08 | 2024-01-02 | Board Of Regents, The University Of Texas System | Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications |
| US11744926B2 (en) | 2010-10-08 | 2023-09-05 | Board Of Regents, The University Of Texas System | Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications |
| US9656001B2 (en) | 2010-10-08 | 2017-05-23 | Board Of Regents, The University Of Texas System | Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications |
| JP2013544549A (ja) * | 2010-10-08 | 2013-12-19 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム | 生物医学的応用のためのアルギン酸塩及びヒアルロン酸を用いる抗癒着性バリア膜 |
| US10850011B2 (en) | 2012-12-11 | 2020-12-01 | Board Of Regents, The University Of Texas | Hydrogel membrane for adhesion prevention |
| US10272184B2 (en) | 2012-12-11 | 2019-04-30 | Board Of Regents, The University Of Texas System | Hydrogel membrane for adhesion prevention |
| US11565027B2 (en) | 2012-12-11 | 2023-01-31 | Board Of Regents, The University Of Texas System | Hydrogel membrane for adhesion prevention |
| JP2016502874A (ja) * | 2012-12-11 | 2016-02-01 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 癒着防止のためのハイドロゲル膜 |
| US12453804B2 (en) | 2012-12-11 | 2025-10-28 | Board Of Regents, The University Of Texas System | Hydrogel membrane for adhesion prevention |
| WO2014192807A1 (ja) * | 2013-05-29 | 2014-12-04 | 株式会社大塚製薬工場 | 癒着防止材 |
| JP2018149414A (ja) * | 2013-05-29 | 2018-09-27 | 株式会社大塚製薬工場 | 癒着防止材 |
| US9901662B2 (en) | 2013-05-29 | 2018-02-27 | Otsuka Pharmaceutical Factory, Inc. | Adhesion preventing material |
| JPWO2014192807A1 (ja) * | 2013-05-29 | 2017-02-23 | 株式会社大塚製薬工場 | 癒着防止材 |
| WO2022070845A1 (ja) * | 2020-09-29 | 2022-04-07 | 日東電工株式会社 | 発泡体及びその製造方法 |
| US11771122B2 (en) | 2020-09-29 | 2023-10-03 | Nitto Denko Corporation | Foam body and method for manufacturing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| IL193640A0 (en) | 2009-05-04 |
| CA2643083A1 (en) | 2007-09-13 |
| EP1988942A2 (en) | 2008-11-12 |
| IL193621A (en) | 2013-08-29 |
| CA2643084A1 (en) | 2007-09-13 |
| AU2007224138B2 (en) | 2012-07-19 |
| BRPI0708422A2 (pt) | 2011-05-31 |
| BRPI0708429A2 (pt) | 2011-05-31 |
| JP2009528437A (ja) | 2009-08-06 |
| US20070254016A1 (en) | 2007-11-01 |
| WO2007103209A2 (en) | 2007-09-13 |
| US20080033392A1 (en) | 2008-02-07 |
| WO2007103208A3 (en) | 2008-12-24 |
| US9028872B2 (en) | 2015-05-12 |
| IL193621A0 (en) | 2009-05-04 |
| EP1988937A2 (en) | 2008-11-12 |
| WO2007103209A3 (en) | 2008-12-24 |
| IL193640A (en) | 2012-12-31 |
| NO20083729L (no) | 2008-11-12 |
| CA2643084C (en) | 2015-12-29 |
| ATE517645T1 (de) | 2011-08-15 |
| AU2007224137A1 (en) | 2007-09-13 |
| NO20083696L (no) | 2008-11-12 |
| EP1988942B1 (en) | 2011-07-27 |
| WO2007103208A2 (en) | 2007-09-13 |
| AU2007224138A1 (en) | 2007-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9028872B2 (en) | Gelled composite | |
| JP5328780B2 (ja) | アルギネート被覆多糖ゲル含有発泡体複合物、その製法および用途 | |
| Levengood et al. | Chitosan-based scaffolds for bone tissue engineering | |
| Barbosa et al. | Polysaccharides as scaffolds for bone regeneration | |
| Christensen | Alginates as biomaterials in tissue engineering | |
| US11168183B2 (en) | Method for the production of hydrogel comprising chitosan and negatively charged polyelectrolytes, and cellular, porous material resulting from said hydrogel | |
| CN101227913A (zh) | 自胶凝的藻酸盐体系及其用途 | |
| US10781293B2 (en) | Process for preparing biocompatible and biodegradable porous three-dimensional polymer matrices and uses thereof | |
| CN110869065A (zh) | 包含硅酸钙的结缔组织例如骨、牙本质或牙髓再生材料 | |
| CN101401969B (zh) | 胶原-壳聚糖-羟基磷灰石球形多孔颗粒材料的制备方法 | |
| Mohanraj | Plant-derived resorbable polymers in tissue engineering | |
| ES2368516T3 (es) | Material compuesto gelificado. | |
| EP3697461B1 (en) | Porous material | |
| Maillard et al. | Double-network polysaccharide hydrogel for guided tissue repair | |
| Majidi et al. | The Role of Alginate in Scaffold Design for Tissue Engineering Applications | |
| Pal et al. | Natural Polymers: Tissue Engineering | |
| Waly et al. | Evaluation of Hybrid Chitosan-Cellulose Biodegradable Scaffolds for Tissue Engineering Applications | |
| JP2000230002A (ja) | 骨修復材 | |
| JP2017507669A (ja) | 細胞培養用材料、製造方法及びその使用 | |
| de Freitas | Chitosan matrices for cell-based bone regenerative therapies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100223 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100223 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20120216 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120904 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121204 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20121204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121204 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130402 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130802 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130814 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20131004 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150313 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151009 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20160322 |